The CEO's sustained selling — 14 transactions in 5 weeks plus this new 144 — signals a lack of confidence at the top. With a micro-cap biotech ($11M market cap) and no disclosed positive catalysts, traders should watch for further insider sales or a potential liquidity event.
Price Chart
Executive Summary
CEO Quang X. Pham filed a Form 144 on June 15, 2026, indicating intent to sell 40,000 shares of Cadrenal Therapeutics common stock, with an approximate market value of $148,400 based on the filing date. This follows an extensive insider selling pattern of 14 prior transactions in the past month totaling ~$257K, and the filing itself is part of a sustained liquidation trend by the CEO.
Key Facts
- CEO Quang X. Pham filed Form 144 to sell 40,000 shares valued at ~$148,400.
- Pham has executed 14 separate sales between May 11 and June 12, 2026, totaling ~$257K.
- The filing notes 'Locking in the four-week average for week ending 6/12/26 for 332,006 shares' — suggesting a systematic selling plan.
- Market cap is only ~$11M, making this proposed sale ~1.3% of the company.
- Prior insider activity (30d) shows 10 sells totaling $154K, consistent with this pattern.
Financial Impact
Proposed sale of 40,000 shares (~$148K) represents ~1.3% of the $11M market cap. Combined with recent sales, total CEO liquidation exceeds $400K in ~5 weeks.
Risk Factors
- CEO may continue selling, further pressuring the stock.
- No disclosed positive catalysts to offset insider liquidation.
- Micro-cap biotech with low liquidity — selling pressure can have outsized impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-043385 |
| Document: 0001628280-26-043385-index.html | 0001628280-26-043385 |
| Document: 0001628280-26-043385.txt | 0001628280-26-043385 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $0.9723 | awaiting T+60 | — | $0.9100 (−6.41%) |
Aug 31, 2026 8w ago | 8-K | $1.75 | awaiting T+60 | — | $0.9100 (−48.00%) |
Jul 21, 2026 13w ago | 8-K | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 21, 2026 13w ago | EFFECT | $2.17 $0.9970 | ▼ −54.06% | ▼ −58.03% | $0.9100 (−58.06%) |
Jul 1, 2026 16w ago | Press Release | $3.60 $1.12 | ▲ +68.89% | ▲ +71.94% | $0.9100 (+74.72%) |
Jun 29, 2026 16w ago | 8-K | $3.34 $1.32 | ▼ −60.48% | ▼ −64.04% | $0.9100 (−72.75%) |
Jun 18, 2026 18w ago | 8-K | $3.50 $1.06 | ▼ −69.71% | ▼ −71.61% | $0.9100 (−74.00%) |
Jun 15, 2026 18w ago | 144 | $3.04 $1.18 | ▲ +61.18% | ▲ +62.18% | $0.9100 (+70.07%) |
May 7, 2026 24w ago | Press Release | $6.02 $1.96 | ▼ −67.44% | ▼ −71.27% | $0.9100 (−84.88%) |
Apr 30, 2026 25w ago | 8-K | $6.67 $2.06 | ▼ −69.12% | ▼ −72.22% | $0.9100 (−86.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers